Skip to content

Immunome

US · IMNM #2671 by market cap Listed 2020
18.80 -0.30 -1.54%
Live - 5344 symbols - heartbeat 566s ago · 2026-10-08 09:59
Pre-market 19.02 -0.39%
After-hours 19.10 0.00%
Market cap
2.22B
P/B
4.22
EPS
-2.43
Reader sentiment Are you bullish or bearish on IMNM?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 4.34 In line with history 66th percentile
5-year average 14.07 · #362 of 514 in Biotechnology
P/E ratio -7.63 Cheap vs history 17th percentile
5-year average -3.86 · forward -7.38
P/S ratio 567.53 Expensive vs history 94th percentile
5-year average 113.45 · forward 323.73 · #335 of 388 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Immunome (IMNM) 2.22B -7.43 4.22 0.00%
Vertex Pharmaceuticals (VRTX) 128.41B 29.51 6.34 0.00%
Moderna (MRNA) 78.42B -24.61 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 75.37B 18.12 2.38 0.50%
argenx SE (ARGX) 51.17B 31.00 6.08 0.00%
Revolution Medicines (RVMD) 40.35B -21.22 15.48 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value22.58 Economic moatNone UncertaintyVery High

Trading 20.1% below Morningstar's fair value estimate.

Fair value

Immunome Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% discount to our quantitative fair value estimate of $22.58 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet bolsters our estimated valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 15.1, which sits in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.8, a core component of valuation, sits in the bottom 20% compared with peers globally. Although the firm's market value of equity makes up a large share of enterprise value, it suggests that the company isn't overly leveraged and may even have capacity to raise debt to fund additional growth investments. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 09:59:59 · For reference only, not investment advice and not tailored to your situation.